Press releases

These press releases are intended for business journalists and analysts/investors

Breo® Ellipta® (fluticasone furoate/vilanterol) to be PBS listed as reimbursed treatment for asthma and COPD

Affordable treatment options for Australian patients with asthma and chronic obstructive pulmonary disease (COPD) are set to expand with GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) announcing the listing of Breo Ellipta on the Pharmaceutical Benefits Scheme (PBS) from 1st December 2014.

Read more - Breo® Ellipta® (fluticasone furoate/vilanterol) to be PBS listed as reimbursed treatment for asthma and COPD Read more

Arzerra® (ofatumumab) registered in Australia for first-line use in chronic lymphocytic leukaemia (CLL)

Arzerra® (ofatumumab) registered in Australia for first-line use in combination with chlorambucil or bendamustine, for the treatment of patients with chronic lymphocytic leukaemia (CLL) who have not received prior therapy and are inappropriate for fludarabine-based therapy.

Read more - Arzerra® (ofatumumab) registered in Australia for first-line use in chronic lymphocytic leukaemia (CLL) Read more